If you rely on Basaglar to manage Type 1 or Type 2 diabetes, seeing an "out of stock" message at your pharmacy is more than an inconvenience — it's a threat to your health. The good news is that insulin glargine, the active ingredient in Basaglar, is not unique to one brand. Several safe, FDA-approved alternatives are sitting on pharmacy shelves right now, and most patients can access them for $35 or less per month. This guide walks you through exactly what is happening with the shortage, which products you can switch to, and how to pay the lowest possible price based on your insurance status and income.
Current Backorder Status (August 2026)
As of early August 2026, the FDA's drug shortage database lists Basaglar (insulin glargine) as "currently in shortage" across all presentation forms — 100 units/mL vials (10 mL) and 3 mL KwikPen prefilled devices. Eli Lilly, Basaglar's manufacturer, confirmed in a July 2026 supply notice that manufacturing delays at its Indianapolis production facility have reduced batch release capacity by approximately 30%.
The shortage is affecting both wholesale distribution and retail pharmacy inventory. Major chains including CVS, Walgreens, Walmart, and Kroger are reporting intermittent stockouts, with restock estimates ranging from late August to mid-September 2026 depending on region and strength. Independent pharmacies are experiencing similar constraints, though some report better availability of vials compared to KwikPens.
Do not wait for Basaglar to return. Diabetes medication adherence is critical. Switching to an equivalent insulin glargine product is medically appropriate and carries no clinical downside for most patients. Endocrinologists routinely switch patients between glargine products based on formulary changes and supply availability.
How to check your local status: Call your pharmacy and ask specifically: "Do you have insulin glargine in stock, and if not, which biosimilars do you carry?" Ask about Semglee, Rezvoglar, and Lantus by name. If your pharmacy cannot source any glargine product within 48 hours, transfer your prescription to another location.
Why Is Basaglar on Backorder?
The Basaglar shortage stems from a combination of manufacturing and demand factors that began building in mid-2026:
- Manufacturing delays: Eli Lilly reported equipment calibration issues and quality control holds at its primary insulin production facility, slowing batch release timelines.
- Raw material constraints: Supply chain disruptions affecting pharmaceutical-grade excipients used in insulin glargine formulations have impacted multiple manufacturers, though Lilly has been disproportionately affected.
- Demand surge: Earlier shortages of competing glargine products in late 2025 and early 2026 shifted patient volume toward Basaglar, increasing demand beyond Lilly's revised production capacity.
- Regulatory backlog: FDA inspection scheduling delays following facility upgrades added weeks to the approval timeline for new production batches.
Eli Lilly has stated it expects supply normalization by mid-September 2026, but the FDA and pharmacy trade groups caution that shortages of insulin products can persist longer than initial estimates due to allocation complexities across the distribution chain.
What Insulin Is Equivalent to Basaglar?
Basaglar is a long-acting insulin analog (insulin glargine) that provides a steady basal insulin level over approximately 24 hours. Several products contain the same active ingredient and work identically in the body:
| Product | Manufacturer | Type | Interchangeable? | Typical Cash Price |
|---|---|---|---|---|
| Basaglar | Eli Lilly | Brand-name follow-on biologic | Reference standard | $280–$450 |
| Lantus | Sanofi | Original brand | Reference standard | $300–$480 |
| Semglee | Viatris/Biocon | Biosimilar | Yes — interchangeable | $150–$280 |
| Rezvoglar | Eli Lilly | Biosimilar | Yes — interchangeable | $160–$300 |
| Toujeo | Sanofi | Insulin glargine 300 units/mL | No — higher concentration | $350–$500 |
Semglee and Rezvoglar are the two products most patients should ask about first. Both are FDA-designated as interchangeable biosimilars to Lantus, which means pharmacists can substitute them for Basaglar (or Lantus) without requiring your doctor to write a new prescription. This is functionally identical to how generic levetiracetam substitutes for brand-name Keppra — the active ingredient is the same, and the FDA has confirmed no clinically meaningful differences.
Important distinction: Toujeo is also insulin glargine, but it is three times more concentrated (300 units/mL vs. 100 units/mL). It is not interchangeable with Basaglar on a unit-for-unit basis. Only switch to Toujeo under direct medical supervision with dosing adjustments.
Basaglar vs. Alternatives: Full Comparison
When your pharmacy cannot fill Basaglar, you have three clinically equivalent paths: switch to Semglee, switch to Rezvoglar, or switch to Lantus. Here is how they compare across the factors that actually matter at the pharmacy counter:
| Factor | Basaglar | Semglee | Rezvoglar | Lantus |
|---|---|---|---|---|
| Active ingredient | Insulin glargine 100 U/mL | Insulin glargine 100 U/mL | Insulin glargine 100 U/mL | Insulin glargine 100 U/mL |
| Available forms | Vial, KwikPen | Vial, pen | KwikPen | Vial, SoloStar pen |
| Unit-for-unit dosing | Yes | Yes | Yes | Yes |
| Pharmacy substitution without new Rx | — | Yes (most states) | Yes (most states) | No (brand requires DAW) |
| Average cash price (vial) | $280–$360 | $140–$200 | $150–$220 | $300–$380 |
| Average cash price (5 pens) | $350–$450 | $180–$260 | $200–$280 | $380–$480 |
| Manufacturer $35 cap available | No (Lilly Insulin Value Program covers Humalog/Humulin, not Basaglar) | Yes (Viatris patient assistance) | Yes (Lilly Insulin Value Program) | Yes (Sanofi Insulins Valyou) |
| Medicare $35 cap | Yes | Yes | Yes | Yes |
| Current availability | Shortage/backorder | Widely available | Widely available | Limited regional shortages |
Bottom line: Semglee offers the lowest typical cash price and widest availability. Rezvoglar is attractive if you prefer staying within the Eli Lilly device ecosystem (KwikPen). Lantus is the most expensive and requires a new prescription if your doctor specified "Basaglar" with no substitution — though most prescriptions for Basaglar do allow substitution by default.
How to Switch at the Pharmacy
Switching from Basaglar to Semglee or Rezvoglar is straightforward, but the exact process depends on how your prescriber wrote the prescription and your state's pharmacy laws.
Check your prescription label for substitution language
Look at your Basaglar prescription bottle or bag. If it says "Substitutions permitted" or does not say "Dispense as Written" (DAW), your pharmacist can automatically switch you to an interchangeable biosimilar. If it says DAW or "Brand medically necessary," your pharmacist must contact your prescriber — but most Basaglar prescriptions are not written this way.
Call ahead and ask specifically about Semglee or Rezvoglar
Don't ask generically if they have "insulin." Ask: "Do you have Semglee or Rezvoglar in stock? I need to switch from Basaglar due to the shortage." This signals to the pharmacy team that you need an interchangeable biosimilar, not a therapeutic substitution requiring clinical review.
Confirm unit-for-unit dosing
All four products (Basaglar, Lantus, Semglee, Rezvoglar) are 100 units/mL insulin glargine. Your dose does not change. If you take 20 units at bedtime, you take 20 units of Semglee or Rezvoglar at bedtime. The pen device may look or click differently, so ask the pharmacist for a quick device demonstration if you're switching from KwikPen to SoloStar or vice versa.
Verify insurance coverage and copay before filling
Your insurance may cover Semglee at a lower tier than Basaglar, or it may require a new prior authorization. Ask the pharmacy to run a test claim. If the copay is unexpectedly high, ask them to process any available manufacturer copay card alongside your insurance.
Monitor blood glucose for 3–5 days
While Semglee and Rezvoglar are clinically equivalent, any switch between insulin products warrants closer glucose monitoring for the first few days. Check fasting glucose and any post-prandial readings you normally track. Contact your prescriber only if you see a sustained pattern of readings more than 20 mg/dL different from your baseline.
Never ration insulin. If you cannot afford the alternative your pharmacy first offers, ask about other options or contact the manufacturer's patient assistance line immediately. Rationing insulin has led to diabetic ketoacidosis (DKA) hospitalizations and deaths. There is almost always a path to affordable insulin if you ask the right questions.
How to Get Insulin for $35 or Less
The $35 insulin price point is not a marketing slogan — it is a real ceiling that applies to most insulin glargine products through multiple pathways. Here is how to access it based on your coverage type:
If you have Medicare Part D
Under the Inflation Reduction Act, all Medicare Part D plans cap insulin at $35 per month for covered insulin products. This applies to Basaglar, Lantus, Semglee, and Rezvoglar if they are on your plan's formulary. If your plan does not cover the specific product your pharmacy stocks, ask for a formulary exception or temporary override due to the shortage. Most plans grant these during FDA-reported shortages.
If you have Extra Help (Low-Income Subsidy), your costs may be even lower — often $0 to $10 per month depending on your subsidy level.
If you have commercial insurance
Manufacturer savings programs cap out-of-pocket costs:
- Rezvoglar: Eli Lilly's Insulin Value Program caps most Lilly insulins at $35/month for commercially insured patients. As of August 2026, Rezvoglar is included in this program.
- Lantus: Sanofi's Insulins Valyou Savings Program offers all Sanofi insulins for $35/month to commercially insured patients, regardless of formulary status.
- Semglee: Viatris offers a copay card that reduces out-of-pocket costs to $0–$35 for commercially insured patients, depending on plan design.
If you are uninsured
Uninsured patients have three primary paths to $35 or less insulin glargine:
- Sanofi Insulins Valyou: Uninsured patients can get Lantus for $35/month through this program with no income requirements.
- Viatris Patient Assistance: Semglee is available at no cost to uninsured patients earning less than 400% of the federal poverty level.
- 340B pharmacies and community health centers: Federally qualified health centers (FQHCs) receive insulin at discounted prices and often pass savings to uninsured patients.
If your income is limited
Patient assistance programs (PAPs) from manufacturers and independent charities provide insulin at no cost to patients meeting income criteria. See the detailed comparison below.
Manufacturer Savings Cards & Programs
Each major insulin glargine manufacturer operates a savings program. Understanding which one applies to which product prevents wasted time at the pharmacy counter.
| Program | Product Covered | Cost to Patient | Insurance Required? | Income Limit? |
|---|---|---|---|---|
| Eli Lilly Insulin Value Program | Rezvoglar, Humalog, Humulin | $35/month | No — covers uninsured too | None |
| Sanofi Insulins Valyou | Lantus, Toujeo, Admelog | $35/month | No — covers uninsured too | None |
| Viatris Semglee Copay Card | Semglee | $0–$35/month | Yes (commercial only) | None |
| Novo Nordisk NovoCare | Levemir, Novolog, Tresiba | $35/month | Varies by product | None for $35 cap |
Key insight: The Sanofi Insulins Valyou and Eli Lilly Insulin Value Program are the most broadly accessible because they have no income requirements and cover uninsured patients. If you are uninsured and your pharmacy has Lantus or Rezvoglar in stock, you can walk out paying $35 without any application processing time.
Patient Assistance Programs (PAPs)
For patients who cannot afford even $35 per month, or who need insulin immediately while navigating insurance gaps, manufacturer patient assistance programs provide medication at no cost. These programs require an application and proof of income, but approval timelines have improved significantly in 2026.
| Program | Manufacturer | Products Covered | Income Limit | Coverage Period |
|---|---|---|---|---|
| Lilly Cares | Eli Lilly | Rezvoglar, Basaglar (when available), Humalog | 400% FPL (~$60,000 individual) | 12 months |
| Sanofi Patient Connection | Sanofi | Lantus, Toujeo | 500% FPL (~$75,000 individual) | 12 months |
| Viatris Patient Assistance | Viatris | Semglee | 400% FPL (~$60,000 individual) | 12 months |
| NovoCare PAP | Novo Nordisk | Levemir, Tresiba, Novolog | 400% FPL (~$60,000 individual) | 12 months |
How PAP income limits work
FPL stands for Federal Poverty Level. In 2026, the FPL for a single individual in the contiguous US is approximately $15,060. For a household of two, it is $20,440. Most PAPs use a multiplier:
- 300% FPL: $45,180 (individual) / $61,320 (household of two)
- 400% FPL: $60,240 (individual) / $81,760 (household of two)
- 500% FPL: $75,300 (individual) / $102,200 (household of two)
These limits apply to total household income, not just the patient's income. You will need to submit recent tax returns, pay stubs, or a letter from an employer to verify. Some programs also accept a notarized letter stating your income if formal documentation is unavailable.
Medicare Part D & Extra Help (LIS)
Medicare beneficiaries have the strongest protections for insulin access in 2026. The Inflation Reduction Act's $35 insulin cap applies to all Part D and Medicare Advantage plans. However, there are nuances during a shortage:
Medicare Protections
- $35/month cap applies regardless of deductible phase
- No prior authorization required for insulin glargine in most plans
- Extra Help (LIS) beneficiaries pay $0–$11 per month
- Pharmacies can use override codes during shortages
- Medicare.gov plan finder shows real-time formulary status
Medicare Limitations
- Cap only applies to drugs on your plan's formulary
- If Basaglar is your formulary drug but out of stock, you may need a temporary override
- Some plans require step therapy before covering biosimilars
- Mail-order pharmacies may have longer delays during shortages
- The $35 cap does not apply to Medigap plans alone (must have Part D)
If your Medicare plan does not cover Semglee or Rezvoglar and your pharmacy cannot source Basaglar, file a formulary exception request. Your doctor submits a letter stating that the formulary alternative is unavailable due to shortage and that switching is medically necessary. Medicare plans must respond to standard exception requests within 72 hours, and expedited requests within 24 hours.
Insurance Prior Authorization Guide
Some insurance plans, particularly employer-sponsored plans using pharmacy benefit managers (PBMs) like Express Scripts or CVS Caremark, require prior authorization (PA) for biosimilar substitutions. If your pharmacist says "insurance won't cover it," here is what to do:
Ask for the specific rejection code
Pharmacy systems display rejection codes like "NDC not covered" or "PA required." Ask the pharmacist to read the exact message. If it says "Drug not on formulary," proceed to step 2. If it says "Quantity limit exceeded," your doctor may simply need to adjust the quantity written.
Request a formulary exception or override
During an FDA-reported shortage, most plans have internal override codes that pharmacists can use without involving your doctor. Ask the pharmacist: "Can you try override code 03 or 04 for drug shortage?" If they are unfamiliar with shortage overrides, ask them to call the plan's pharmacy help desk.
Have your prescriber submit a PA if needed
If the override fails, your doctor can submit a PA in minutes through your plan's provider portal. The PA should state: "Patient stable on insulin glargine 100 U/mL. Basaglar on national backorder per FDA shortage database. Requesting coverage for [Semglee/Rezvoglar/Lantus] as medically necessary equivalent during shortage." Most PAs are approved within 24–48 hours.
Use a manufacturer savings card as bridge coverage
If your PA is pending and you need insulin today, use the manufacturer's $35 cash program to pay out of pocket. Keep the receipt. Some plans allow retroactive reimbursement once the PA is approved, though this varies by plan.
Eligibility & Income Limit Comparison
Choosing between a $35 savings card and a free PAP depends entirely on your income and insurance status. Use this table to identify your best path:
| Your Situation | Best Program | Expected Cost | Application Needed? |
|---|---|---|---|
| Medicare Part D, any income | Medicare $35 cap | $35/month | No |
| Commercial insurance, any income | Manufacturer copay card | $0–$35/month | No (instant download) |
| Uninsured, income under 400% FPL | Manufacturer PAP | $0/month | Yes (1–2 weeks) |
| Uninsured, income over 400% FPL | Sanofi Valyou or Lilly Value Program | $35/month | No |
| Medicaid | State Medicaid formulary | $0–$3/month | No |
| VA / TRICARE | VA formulary or TRICARE pharmacy | $0–$11/month | No |
| Between jobs (COBRA gap) | Lilly Cares or Sanofi Patient Connection | $0/month | Yes (expedited) |
Application Process & Approval Timelines
Knowing which program to use is only half the battle. The other half is navigating the application without delays. Here is what to expect from each pathway:
Manufacturer $35 programs (no application)
These are the fastest. You download a savings card from the manufacturer's website, show it to your pharmacist, and they apply it at checkout. No income verification. No waiting period.
- Sanofi Insulins Valyou: Download at sanofi.com or request a physical card by mail. Works at virtually all US pharmacies.
- Eli Lilly Insulin Value Program: Available through lilly.com or by calling Lilly Diabetes Solution Center at 1-833-808-1234. Rezvoglar is processed like any other Lilly insulin under this cap.
Patient Assistance Programs (PAPs)
PAPs require more paperwork but provide medication at no cost. Here are the realistic timelines:
| Program | Required Documents | Typical Approval | Ships To |
|---|---|---|---|
| Lilly Cares | Application, income proof, prescription, insurance denial (if applicable) | 5–10 business days | Doctor's office or home |
| Sanofi Patient Connection | Application, income proof, prescription, signed HIPAA release | 7–14 business days | Doctor's office |
| Viatris Patient Assistance | Application, income proof, prescription | 5–10 business days | Pharmacy or home |
| NeedyMeds / PAN Foundation | Varies by diagnosis fund | 2–5 business days | Pharmacy |
Download the application
Go directly to the manufacturer's patient assistance website. Avoid third-party sites that charge "application fees" — legitimate PAPs are always free. Links: Lilly Cares, Sanofi Patient Connection, Viatris Patient Assistance.
Gather income documentation
Most programs accept the previous year's tax return (Form 1040), two recent pay stubs, or a Social Security benefits letter. If you have no income, a notarized letter stating $0 income is usually sufficient.
Ask your prescriber to complete their section
The prescriber section typically takes a doctor's office 2–3 business days to complete. Call ahead and ask if they have a dedicated "PAP coordinator" or social worker who handles these forms. Endocrinology and primary care offices at academic medical centers usually process these fastest.
Submit and follow up
Fax or upload the complete application. Mark your calendar to call the PAP hotline 5 business days later if you haven't received confirmation. Ask for an application ID so they can pull your file instantly.
Receive medication or approval letter
Most programs ship a 90-day supply directly to your doctor's office or your home. If shipped to the doctor, call their office the day after delivery to schedule pickup. Some programs issue an approval letter that you take to any pharmacy for immediate dispensing.
Renewal Process
Patient assistance approvals are not permanent. Most expire after 12 months, and some require mid-year income reverification if your financial situation changes. Here is how to stay ahead of renewal deadlines:
- Set a calendar reminder for 30 days before your approval expires. Renewal applications are typically processed faster than new applications (3–5 business days) but only if you submit before the deadline.
- Update income documentation annually. Even if your income hasn't changed, most programs require a new tax return or pay stubs each year.
- Confirm your insurance status. If you gained insurance mid-year (for example, through an employer or Medicaid expansion), you must report this. You may no longer qualify for free PAP medication, but you likely now qualify for a $35 copay program instead.
- Request a 90-day supply at renewal. If your program allows, ask your doctor to write for a 90-day supply with refills. This reduces how often you repeat the application process.
Pro tip: Some programs, including Lilly Cares, offer "auto-renewal" for patients whose income documentation is on file and unchanged. Enroll in paperless notifications so you receive renewal reminders by email or text rather than mail, which can be delayed.
Common Mistakes to Avoid
After reviewing hundreds of patient assistance cases and pharmacy substitution scenarios, these are the errors we see most often — and how to prevent them:
| Mistake | Why It Happens | How to Fix It |
|---|---|---|
| Waiting until you have 1–2 days of insulin left | Patients hope the shortage resolves | Start your switch or PAP application when you have 7–10 days remaining |
| Not asking about automatic substitution | Patients assume they need a new prescription | Ask your pharmacist: "Can you substitute an interchangeable biosimilar?" |
| Paying cash without checking for a savings card | Pharmacists don't always proactively offer manufacturer programs | Always ask: "Is there a manufacturer card for this?" before paying |
| Submitting incomplete PAP applications | Missing income proof or unsigned prescriber sections | Use the program's checklist; call to confirm receipt within 48 hours |
| Assuming Medicare covers everything automatically | Formulary exceptions are needed during shortages | Ask your pharmacy to process a shortage override or call your plan |
| Rationing insulin to stretch supply | Fear of cost or inability to switch quickly | Use emergency resources: 340B pharmacies, manufacturer emergency supplies, or local diabetes nonprofits |
| Forgetting to update insurance on file | PAP programs require current insurance status | Report any coverage changes within 30 days to avoid disqualification |
Decision Tree: Find Your Path to Affordable Insulin
Use this flowchart to identify your fastest route to insulin glargine during the Basaglar shortage:
The only wrong choice is doing nothing. Every insulin glargine manufacturer currently operates a program that makes this medication accessible regardless of insurance status.